News - Greater Bay Area International Clinical Trial Institute

18.09.2025

GBAICTI Reaffirms Support for the Policy Address in Promoting the Development of the Life and Health Technology Industry

The 2025 Policy Address provides a powerful blueprint for Hong Kong's future as an international health and medical innovation hub, with a strategic focus on attracting companies to conduct clinical trials for rare diseases drugs, high-end cancer drugs, and advanced therapy products.

09.09.2025

GBAICTI, HKUMed and GSK signed the Tripartite Memorandum of Understanding

The Greater Bay Area International Clinical Trial Institute, the Department of Pharmacology and Pharmacy of the LKS Faculty of Medicine, The University of Hong Kong, and GSK signed a tripartite Memorandum of Understanding. The three parties jointly established a strategic framework to advance clinical data and real-world studies in the Greater Bay Area.

22.08.2025

GBAICTI and Bay Trial Advanced Collaborative Efforts in Strategic Meeting

GBAICTI and Bay Trial held a regular meeting to advance their collaborative platform, focusing on the practical implementation of talent exchange, joint branding, and knowledge-sharing initiatives to jointly promote clinical research development in the GBA.

19.08.2025

GBAICTI Showcased Hong Kong's Clinical Trial Strengths to Visiting Greater Bay Area Biomedical Delegation

GBAICTI presented Hong Kong's unique clinical trial advantages to a delegation of over 30 biomedical enterprise representatives from the Greater Bay Area, fostering cross-border collaboration in medical innovation.

12.08.2025

HKUMed, SMART and GBAICTI Met in Hong Kong to Foster Talent Exchange and Collaboration

On August 12, 2025, Prof. Bernard Cheung, CEO of GBAICTI, and Prof. CS Lau, Dean of HKUMed, met in Hong Kong with Prof. Nieng Yan, Founding President of Shenzhen Medical Academy of Research and Translation (SMART).

31.07.2025

GBAICTI Engaged With About 100 Industry Representatives to Enhance Hong Kong's Clinical Research Development

At a sharing session hosted by the Hospital Authority, the Greater Bay Area International Clinical Trial Institute (GBAICTI) engaged in-depth with around 100 industry representatives from over 30 companies to discuss enhancement measures and the future development of clinical trials in Hong Kong.